Cover Image

Severe hypereosinophilia in a patient treated with dupilumab and shift to mepolizumab: the importance of multidisciplinary management. A case report and literature review

Type 2 inflammation is a heterogeneous condition due to the complex activation of different immunological pathways. Rapid progress in research to evaluate the efficacy of biologics for chronic rhinosinusitis with nasal polyps and asthma has led to the availability of effective therapeutic options. T...

Full description

Saved in:

Bibliographic Details
Main Authors:	Sara Munari (Author), Giulia Ciotti (Author), Walter Cestaro (Author), Lorenzo Corsi (Author), Silvia Tonin (Author), Andrea Ballarin (Author), Ariel Floriani (Author), Cristina Dartora (Author), Annamaria Bosi (Author), Matteo Tacconi (Author), Francesco Gialdini (Author), Michele Gottardi (Author), Francesco Menzella (Author)
Format:	Book
Published:	BioExcel Publishing Ltd, 2024-05-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Uveitis and hypereosinophilia associated with dupilumab in an atopic dermatitis patient
by: Shiyu Zhang, et al.
Published: (2023)

Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab
by: Erminia Ridolo, et al.
Published: (2020)

Very long-term data on patients with severe eosinophilic asthma treated with mepolizumab: a case series
by: Carlo Lombardi, et al.
Published: (2024)

Prolonged hypereosinophilia associated with dupilumab for atopic dermatitis: A case series and review of literature
by: Gabriela Fonseca, BS, et al.
Published: (2024)

Clinical usefulness of mepolizumab in severe eosinophilic asthma
by: Menzella F, et al.
Published: (2016)

Tralokinumab as an Alternative to Dupilumab in a Patient with Atopic Dermatitis and Asthma who Developed Hypereosinophilia: A Case Report
by: Ilaria Trave, et al.
Published: (2024)

Successful use of antihistamines in severe hypereosinophilia
by: Stefano Vallero, et al.
Published: (2012)

Near-fatal asthma responsive to mepolizumab after failure of omalizumab and bronchial thermoplasty
by: Menzella F, et al.
Published: (2017)

Lymphoid aggregates in bone marrow biopsies in patients with hypereosinophilia
by: Sharma Seema, et al.
Published: (2008)

Severe Multi-Organ Failure and Hypereosinophilia: When to Call It "Idiopathic"?
by: Massimo Radin MD, et al.
Published: (2018)

Severe Pediatric Asthma Therapy: Mepolizumab
by: Nicola Ullmann, et al.
Published: (2022)

A Study of Glucosylceramide Synthase and Glycolytic Pathway Enzymes in Patients with Hypereosinophilia
by: Lisa Redmond, et al.
Published: (2017)

Use of Mepolizumab in Children and Adolescents with Asthma in the USA
by: Jaclyn Davis, et al.
Published: (2022)

The Prevalence and Associated Risk Factors of Intestinal Protozoan Parasites in Iranian Children with Hypereosinophilia
by: Hossein Mahmoudvand, et al.
Published: (2021)

A case of hypereosinophilia with digital ischaemia successfully treated with intravenous prostaglandin E1
by: M. Kaga, et al.
Published: (2021)

A retrospective analysis of severe asthma treatment with Mepolizumab
by: Mattia Serao, et al.
Published: (2019)

Clinical remission and control in severe asthma: agreements and disagreements
by: Annamaria Bosi, et al.
Published: (2024)

Mepolizumab-responsive recurrent eosinophilic eruption without peripheral eosinophilia
by: Nina B. Curkovic, MD, et al.
Published: (2024)

Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance
by: Adam Kisling, et al.
Published: (2020)

Economic evaluation and budgetary burden of mepolizumab in severe refractory eosinophilic asthma
by: Manuel David Gil-Sierra, et al.
Published: (2019)

A case of chronic eosinophilic pneumonia in a patient treated with dupilumab
by: Menzella F, et al.
Published: (2019)

Physical Activity as a New Tool to Evaluate the Response to Omalizumab and Mepolizumab in Severe Asthmatic Patients: A Pilot Study
by: Giovanna Elisiana Carpagnano, et al.
Published: (2020)

Earlier continuous administration of mepolizumab for eosinophilic granulomatosis with polyangiitis based on cutaneous findings
by: Takaharu Ikeda, et al.
Published: (2023)

Effectiveness and safety of mepolizumab in severe refractory eosinophilic asthma: results in clinical practice
by: Olalla Montero-Pérez, et al.
Published: (2019)

Cost-effectiveness analysis of the use of mepolizumab in omalizumab-resistant patients with severe asthma
by: A. G. Tolkushin, et al.
Published: (2019)

Omalizumab and mepolizumab in the landscape of biological therapy for severe asthma in children: how to choose?
by: Mattia Giovannini, et al.
Published: (2019)

A term infant with severe hypereosinophilia secondary to CMV infection and the STAT1 gene mutation: a case report
by: Shaimaa Salah, et al.
Published: (2024)

Portal vein thrombosis and food protein-induced allergic proctocolitis in a premature newborn with hypereosinophilia: a case report
by: Cheong-Jun Moon, et al.
Published: (2021)

Idiopathic hypereosinophilic syndrome with eosinophilic cellulitis-like cutaneous involvement treated with mepolizumab and dapsone
by: Madeleine Lachance, MD, et al.
Published: (2022)

Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab
by: Pelaia C, et al.
Published: (2017)

Potential impact of mepolizumab in stepping down anti-osteporotic treatment in corticosteroid-dependent asthma
by: Christian Domingo, et al.
Published: (2023)

A real-world disproportionality analysis of mepolizumab based on the FDA adverse event reporting system
by: Huqun Li, et al.
Published: (2023)

Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care
by: Cosimo Galletti, et al.
Published: (2023)

Multidisciplinary approach to Gorlin-Goltz syndrome: from diagnosis to surgical treatment of jawbones
by: Francesco Spadari, et al.
Published: (2022)

Mepolizumab Therapy for Recalcitrant Eosinophilic Annular Erythema in an Adult: A Case Report and Review of Treatment Options
by: Magdalena Żychowska, et al.
Published: (2020)

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database
by: Fan Zou, et al.
Published: (2023)

Mepolizumab in Severe Pediatric Asthma: Certainties and Doubts through a Single-Center Experience and Review of the Literature
by: Marco Maglione, et al.
Published: (2024)

Efficacy of Mepolizumab in the Treatment of Severe Asthma with a Mixed Granulocytic Pattern of Airway Inflammation (Case Report)
by: A. M. Gubareva, et al.
Published: (2024)

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy
by: Faverio P, et al.
Published: (2018)

Long-term effects of mepolizumab in patients with severe eosinophilic asthma: a 6-year real-life experience
by: Anna Agnese Stanziola, et al.
Published: (2024)